GlassScriptPhysician profile
Misam Zawit
NPI 1861757494
$11,065.90
in general payments reported to CMS, 2019-2025
13 companies · $10K in 2025
The $10K reported for 2025 was more than what 78% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $213 · 2023: $189 · 2024: $280 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,675 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,989 · Food and Beverage: $680 · Education: $246 · Travel and Lodging: $37.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,675.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,989.00 |
| Food and Beverage | $680.45 |
| Education | $245.68 |
| Travel and Lodging | $37.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,080.93 | 2025 | Ojjaara |
| Syndax Pharmaceuticals, INC. | $3,756.59 | 2025 | Revuforj |
| Novartis Pharmaceuticals Corporation | $2,305.91 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $210.56 | 2022-2025 | |
| Celgene Corporation | $125.00 | 2021 | |
| Incyte Corporation | $100.31 | 2021 | |
| Seagen INC. | $99.99 | 2023 | |
| Aveo Pharmaceuticals, INC. | $99.99 | 2022 | |
| Rigel Pharmaceuticals, INC. | $91.93 | 2024 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $89.00 | 2023 | |
| Lilly USA, LLC | $56.69 | 2024 | |
| Pfizer INC. | $25.79 | 2024 | |
| Servier Pharmaceuticals LLC | $23.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misam Zawit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.